| Latest Forum Topics / Biosensors |
 Post Reply
|
|
Is Biosensors a good buy?
|
|||||
|
crimson
Senior |
26-Jan-2010 14:19
|
||||
|
x 0
x 0 Alert Admin |
Given the current market correction (which i believe only started, more to come likely), i dun think the upcoming report on the 28th Jan would have any effect? maybe a small rebound and drop again? | ||||
| Useful To Me Not Useful To Me | |||||
|
allright
Senior |
26-Jan-2010 08:49
|
||||
|
x 0
x 0 Alert Admin |
Thanks to all the information. All of you are so well researched. Doing a better job than the PR dept at BIG. With these good news streaming in I really hope our patience will finally pay off | ||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
OkieDokie
Member |
25-Jan-2010 13:24
|
||||
|
x 0
x 0 Alert Admin |
Came across this recent article in Europcronline website. Should be a relief for for DES manufacturers, including BIG. NATICK, Mass., Jan. 20 -- Boston Scientific Corporation announced today that the U.S. District Court for the District of Delaware has found all four patents in a suit involving Johnson & Johnson to be invalid. As part of a 2007 suit, Johnson & Johnson alleged that Boston Scientific's PROMUS® Everolimus-Eluting Coronary Stent System infringed these four patents, known as the Wright/Falotico patents. The patents relate to coatings (drug and polymer) for drug-eluting stents. The Court ruled today that a trial on the four patents, which was scheduled to begin February 9, will not proceed. "We are pleased with the Court's finding that all four Johnson & Johnson patents are invalid," said Ray Elliott, President and Chief Executive Officer of Boston Scientific. "Boston Scientific will continue to vigorously defend against any charges of infringement. We continue to attempt to resolve remaining outstanding matters with Johnson & Johnson." |
||||
| Useful To Me Not Useful To Me | |||||
|
XiaoMaGe888
Senior |
25-Jan-2010 10:06
|
||||
|
x 0
x 0 Alert Admin |
0.865 should be a good re-entry level,if not will be 0.90 before 29Jan .CHEERS!!!!!!!!!! |
||||
| Useful To Me Not Useful To Me | |||||
|
gbleng
Member |
24-Jan-2010 23:49
|
||||
|
x 0
x 0 Alert Admin |
Looks like 0.81- 0.82 a good re-entry level. thx gbleng, you are spot on! now what's the good price to enter again?
|
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
investor
Senior |
24-Jan-2010 13:55
|
||||
|
x 0
x 0 Alert Admin |
I just read thru the Nomura report dated 15th Jan 2010 - No mention of their target date for the Japan Approval - could be in earlier reports, which I do not have. All estimated dates of approval are at best only 'estimates', including our own inference. In their recent report, they mentioned the approval of France as a possible catalyst for the stock, But I dont think it matters in the short term because of current mkt conditions. I actually prefer to look at this current Q3 2010 results, to see if they can increase their DES sales from last qtr sales of US$12.8m - in the words of Nomura - can we see 'traction' in their sales. Nomura's target is a 10 % qtr on qtr increase - ie their target is US$14.08 sales. More importantly, the CEO emphasized in the closing minutes of the JP Morgan audio conf, that they are talking to and in discussion on additional strategic relationships. Also, if you listen carefully to the video conf in CRTOLINE.org, where Dr. Abizaid was interviewed - when asked if he were a corporation, - which type of DES would he choose - permanent polymer, biodegradable polymer or no-polymer, - if efficacy is equal, he would go for the no-ploymer to develope. Looks like the bio-freedom has impressed quite a bit - and I would not be surprised if a joint venture in the US or something similar to this is formed, involving the bio-freedom. Also, since Biosensors has got CE mark for the Bio-matrix Flex - How is Terumo going to react ? - Will they also go for this new product to mkt ? and do they have to sign new licensing agreements ? Some food for thought - Not a call to buy/sell |
||||
| Useful To Me Not Useful To Me | |||||
|
JustForFun
Member |
23-Jan-2010 23:42
|
||||
|
x 0
x 0 Alert Admin |
According to Nomura analyst report, Japan approval expected only in 2011-2012
|
||||
| Useful To Me Not Useful To Me | |||||
|
investor
Senior |
23-Jan-2010 17:06
|
||||
|
x 0
x 0 Alert Admin |
In the Biosensor's JP Morgan Healthcare slides, it states that Korea mkt share is 21 % of the Asia pacific mkt of US$800m, ie approx US$168m. (although I dont know why Normura's report on 14th Jan 2010 states that Korea mkt is only US$60m). France mkt is quite big, approx US$300m, again stated in Normura's report. Japan's mkt is approx US$600m, and China's mkt is 46 % of Asia pacific of US800m, ie approx US$368m and growing by double digits. Also, in the slides, Biosensors says that it has been able to garner mkt share of 5-7 %, although, in some geographies, it has seen mkt share in excess of 20 % (probably in some countries, where, the clinical trials took place, and where the physicians involved in the trials have been impressed - my guess). From these data, one can probably surmised the potential new revenue that Biosensors can get from these new mkts. Typically, we can assume that Biosensors can get 1/3 of revenue produced by licensees like Terumo, and these are pure profits, flowing down to the bottomline. Note : Only Korea and France are the new mkts approved so far. Again, these are pure conjections and it remains whether the mgmt can successfully, mkt their product in these new countries. THe mkt sentiment is currently very volatile, and even to some extent bearish, and even if the fundamentals of Biosensors looks OK, it does not mean that the share price will go up. Not a call to buy/sell. |
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
novicealex
Member |
23-Jan-2010 00:23
|
||||
|
x 0
x 0 Alert Admin |
Just for info, Terumo Jan. 28, 2010
http://www.terumo.co.jp/English/ir/ir_events/calendar.html By the way, Biosensor will be announcing their Q3 results for FY2010 on 29 Jan 2010. Let's see if there is good surprise for the investors here. |
||||
| Useful To Me Not Useful To Me | |||||
|
FearValueGreed
Master |
23-Jan-2010 00:21
Yells: "Long Term Timing X Capital = Well Deserved Payout" |
||||
|
x 0
x 0 Alert Admin |
I remember just before the end of 07, this coy got their biomatrix license in Europe and after that lao sai all the way from $1 to 20plus cents. now it is back to its hey days. So that was the market expectation for its potential profit then. hence $1 is the ultimateBeyond that, really need new market or product to push this one , otherwise it would be just another dividend stock if it can maintain its market share,, otherwise it would drift to its death if it starts to develop new product with high capex. Think it did raise monies through placement before. Just be careful. The only likely windfall is a big pharm plant take over it |
||||
| Useful To Me Not Useful To Me | |||||
|
investor
Senior |
23-Jan-2010 00:05
|
||||
|
x 0
x 0 Alert Admin |
THe following are facts concerning the Japan Clinical Trial for the bio-matrix that Terumo is doing in Japan. July 2008 - Terumo mentioned in their qrtly reporting that the Japan clinical trial is in progress. Oct 2008 - Terumo mentioned that the enrollment for the trial has been completed, again in their qrtly reporting. The Japan clinical trial is a 300 patient randomised trial comparing the Bio-matrix against the J&J Cyper DES, and the endpoint is a 9-mths TVF. (mentioned in EuroPcr 2008). THat means that as at of now, the trial 9-mths endpoint has been reached (ie probably in July 2009, last yr). and the results must have been submitted to the Japan health authorites. (My guess) The only puzzling thing is why were the results not published ? However, the fact that the CEO of Biosensors mentioned the Japan Clinical trial as part of ' what is next for Biosensors' as well as the fact that it will contribute greatly to their profitability, in the JP Morgan health conf, augurs well for the trial. Some info for long term investors to digest. Not a call to buy/sell or trade the stock. |
||||
| Useful To Me Not Useful To Me | |||||
|
dinola
Member |
21-Jan-2010 11:30
|
||||
|
x 0
x 0 Alert Admin |
thx gbleng, you are spot on! now what's the good price to enter again?
|
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
crimson
Senior |
21-Jan-2010 10:38
|
||||
|
x 0
x 0 Alert Admin |
Any sifu can advise what's this counter's Resistance/Support level? Thanks! |
||||
| Useful To Me Not Useful To Me | |||||
|
crimson
Senior |
20-Jan-2010 11:43
|
||||
|
x 0
x 0 Alert Admin |
no power liao i think... seems that it will hover around current range before another good news (the upcoming financial report prehaps) pushes it pass .90... i'm guessing price may drop a little due to taking profit/accumulation before shooting up again... my guess only lah  Huat Ah before CNY!
|
||||
| Useful To Me Not Useful To Me | |||||
|
XiaoMaGe888
Senior |
20-Jan-2010 08:54
|
||||
|
x 0
x 0 Alert Admin |
HUAT!!!!!!!!!!!!!!!!!LIAO!!!!!!!!!!!!!!!!!!!!!!!!!!!
|
||||
| Useful To Me Not Useful To Me | |||||
|
Bon3260
Supreme |
20-Jan-2010 08:10
Yells: "Ooo Ooo Aaa Aaa!" |
||||
|
x 0
x 0 Alert Admin |
NEWS RELEASE Biosensors Receives CE Mark Approval for BioMatrix Flex™ Singapore, 20 January 2010 – BioMatrix™ was originally launched in Europe in April 2008, where its unique combination of a Biosensors-developed abluminal biodegradable polymer and proprietary limus drug, Biolimus A9 Mike Kleine, President and CEO, commented, "We are extremely pleased to receive approval of BioMatrix Flex. This approval once again demonstrates our commitment to innovation as well as our ability to accelerate the pace of change. We are excited to offer yet another product to improve patients’ lives." The BioMatrix Flex™ stent will be made available for physicians’ use over the coming months. Biosensors International Group, Ltd. ("Biosensors" or "Company", Bloomberg BIG SP) announced today that it has received CE Mark approval for a new version of its BioMatrix™ drug-eluting stent system, the BioMatrix Flex™. ™, rapidly proved successful. The BioMatrix Flex also incorporates the Company’s abluminal biodegradable polymer and Biolimus A9™. In just two years, the Company has received CE Mark approvals for the first version of its BioMatrix drug-eluting stent (January 2008), its smaller-diameter (2.25 mm) version (March 2009) and finally the BioMatrix Flex (January 2010). ### Media Relations/Investor Relations Contact Biosensors International Group Mr. Loh Chee Mun Senior Vice President Tel: (65) 6213 5708 Email: cm.loh@biosensors.com Media Relations / Investor Relations Firm United States Allen & Caron Inc. Mr. Matt Clawson Executive Vice President, Investor Relations Tel: (1) 949 474 4300 Email: matt@allencaron.com About Biosensors International Group, Ltd Biosensors develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. Biosensors is well-positioned to emerge as a leader in drug-eluting stents and has developed a pipeline of next-generation products that are set to gain market share from traditional therapies such as conventional drug-eluting stents, bare-metal stents and open-heart surgery. It has two separate drug-eluting stent programs, BioMatrix™ and BioFreedom™, a completely polymer-free drug-eluting stent. About BioMatrix™ Stent Family BioMatrix™ offers the unique combination of an innovative anti-restenotic drug, Biolimus A9™, a biodegradable poly-lactic acid polymer (PLA), and an advanced, highly flexible stent designed for enhanced deliverability. BA9™ was designed specifically for use in drug-eluting stent systems. In addition to effective immunosuppressive and anti-inflammatory properties, the drug has a higher lipophilic and hydrophobic profile than other limus analogs, enabling rapid absorption of the drug into the targeted tissue and reduced systemic exposure. Precision automated coating ensures the PLA and drug combination is applied only to the abluminal (outer) surface of the stent. The PLA fully degrades into water and carbon dioxide over a six to nine month period as the drug elutes, ultimately leaving in place a biocompatible stent surface. Forward-Looking Statements Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as "may," "will," "expect," "intend," "estimate," "anticipate," "believe," "project" or "continue" or the negative thereof or other similar words. All forward looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances. |
||||
| Useful To Me Not Useful To Me | |||||
|
crimson
Senior |
19-Jan-2010 15:52
|
||||
|
x 0
x 0 Alert Admin |
haha... i'm not any expert, just observations... anyway, counting down now for shortist kena burn *cross fingers*
|
||||
| Useful To Me Not Useful To Me | |||||
|
XiaoMaGe888
Senior |
19-Jan-2010 14:25
|
||||
|
x 0
x 0 Alert Admin |
Best time to vest!!!!!!!!!!!Huat!!!!!!!!AR!!!!!!!!!! | ||||
| Useful To Me Not Useful To Me | |||||
|
eddie84
Member |
19-Jan-2010 13:49
|
||||
|
x 0
x 0 Alert Admin |
I think now is just short term profit taking. Worth to hold and wait for it to break through the resistance level. | ||||
| Useful To Me Not Useful To Me | |||||
|
gbleng
Member |
19-Jan-2010 10:43
|
||||
|
x 0
x 0 Alert Admin |
Got a feeling that price will hover around the 0.90 level until China approval before it will surge to next resistance level of 1.12 | ||||
| Useful To Me Not Useful To Me | |||||